Cargando…
TLC388 Induces DNA Damage and G2 Phase Cell Cycle Arrest in Human Non-Small Cell Lung Cancer Cells
TLC388, a camptothecin-derivative targeting topoisomerase I, is a potential anticancer drug. In this study, its effect on A549 and H838 human non-small cell lung cancer (NSCLC) cells was investigated. Cell viability and proliferation were determined by thiazolyl blue tetrazolium bromide and clonogen...
Autores principales: | Wu, Kun-Ming, Chi, Chih-Wen, Lai, Jerry Cheng-Yen, Chen, Yu-Jen, Kou, Yu Ru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154561/ https://www.ncbi.nlm.nih.gov/pubmed/32281394 http://dx.doi.org/10.1177/1073274819897975 |
Ejemplares similares
-
Single-Institute Clinical Experiences Using Whole-Field Simultaneous
Integrated Boost (SIB) Intensity-Modulated Radiotherapy (IMRT) and Sequential
IMRT in Postoperative Patients With Oral Cavity Cancer (OCC)
por: Hsieh, Chen-Hsi, et al.
Publicado: (2020) -
Power and Promise of Next-Generation Sequencing in Liquid Biopsies
and Cancer Control
por: Wu, Ting-Miao, et al.
Publicado: (2020) -
Why smokeless tobacco control needs to be
strengthened?
por: Mehrotra, Ravi, et al.
Publicado: (2020) -
Out-of-hospital cardiac arrest
por: Nolan, Jerry P., et al.
Publicado: (2023) -
Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy
por: Huang, Kevin Chih-Yang, et al.
Publicado: (2021)